Biomark Diagnostics Stock Market Value
| BMKDF Stock | USD 0.15 0.01 6.25% |
| Symbol | BioMark |
BioMark Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioMark Diagnostics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioMark Diagnostics.
| 10/13/2024 |
| 12/12/2024 |
If you would invest 0.00 in BioMark Diagnostics on October 13, 2024 and sell it all today you would earn a total of 0.00 from holding BioMark Diagnostics or generate 0.0% return on investment in BioMark Diagnostics over 60 days. BioMark Diagnostics is related to or competes with Neuronetics, Intelligent Bio, Biodesix, Precipio, ProPhase Labs, BioAffinity Technologies, and RadNet. BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and asse... More
BioMark Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioMark Diagnostics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioMark Diagnostics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 38.89 | |||
| Value At Risk | (10.00) |
BioMark Diagnostics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioMark Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioMark Diagnostics' standard deviation. In reality, there are many statistical measures that can use BioMark Diagnostics historical prices to predict the future BioMark Diagnostics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | 0.6611 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioMark Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioMark Diagnostics Backtested Returns
BioMark Diagnostics secures Sharpe Ratio (or Efficiency) of -0.087, which signifies that the company had a -0.087% return per unit of risk over the last 3 months. BioMark Diagnostics exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioMark Diagnostics' Risk Adjusted Performance of (0.05), standard deviation of 5.19, and Mean Deviation of 2.23 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning BioMark Diagnostics are expected to decrease at a much lower rate. During the bear market, BioMark Diagnostics is likely to outperform the market. At this point, BioMark Diagnostics has a negative expected return of -0.45%. Please make sure to confirm BioMark Diagnostics' total risk alpha and the relationship between the kurtosis and period momentum indicator , to decide if BioMark Diagnostics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.12 |
Insignificant predictability
BioMark Diagnostics has insignificant predictability. Overlapping area represents the amount of predictability between BioMark Diagnostics time series from 13th of October 2024 to 12th of November 2024 and 12th of November 2024 to 12th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioMark Diagnostics price movement. The serial correlation of 0.12 indicates that less than 12.0% of current BioMark Diagnostics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.12 | |
| Spearman Rank Test | -0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
BioMark Diagnostics lagged returns against current returns
Autocorrelation, which is BioMark Diagnostics pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BioMark Diagnostics' pink sheet expected returns. We can calculate the autocorrelation of BioMark Diagnostics returns to help us make a trade decision. For example, suppose you find that BioMark Diagnostics has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BioMark Diagnostics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BioMark Diagnostics pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BioMark Diagnostics pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BioMark Diagnostics pink sheet over time.
Current vs Lagged Prices |
| Timeline |
BioMark Diagnostics Lagged Returns
When evaluating BioMark Diagnostics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BioMark Diagnostics pink sheet have on its future price. BioMark Diagnostics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BioMark Diagnostics autocorrelation shows the relationship between BioMark Diagnostics pink sheet current value and its past values and can show if there is a momentum factor associated with investing in BioMark Diagnostics.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.